GlassScriptPhysician profile
Michael Gomendoza
NPI 1174637110
$1,914.88
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $1,275 · 2021: $211 · 2022: $36.11 · 2023: $13.94 · 2024: $69.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.96 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $224.03 | 2019-2021 | |
| Allergan, INC. | $220.96 | 2019-2020 | |
| Pfizer INC. | $217.83 | 2019-2020 | |
| Amgen INC. | $200.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.88 | 2020-2021 | |
| Glaxosmithkline, LLC. | $135.77 | 2020-2021 | |
| Amarin Pharma, INC. | $98.51 | 2020-2021 | |
| Lilly USA, LLC | $89.93 | 2019-2023 | Emgality, Jardiance |
| Kowa Pharmaceuticals America, INC. | $69.44 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $69.03 | 2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $41.86 | 2019-2020 | |
| Genentech USA, INC. | $36.65 | 2020 | |
| Corcept Therapeutics | $36.11 | 2022 | |
| Sanofi Pasteur INC. | $20.46 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $16.96 | 2021 | |
| Digital Diagnostics INC. | $16.96 | 2019 | |
| Dermira, INC. | $16.67 | 2020 | |
| Abbvie INC. | $15.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gomendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.